Sentinel node mapping and ductal carcinoma in situ
- 93 Downloads
Pure ductal carcinoma in situ (DCIS) is typically unassociated with a risk of regional lymph node involvement. Retrospective series maintain that larger tumors or high-grade histopathology may harbor a risk of lymph node involvement.
Our community hospital retrospectively reviewed a series wherein women with DCIS were subjected to sentinel lymph node biopsy based on large tumor size and/or high-grade histopathology.
Materials and methods
232 consecutive women with a diagnosis of pure DCIS were evaluated independently by two breast surgeons, one who typically offers sentinel node mapping to patients with tumors larger than 10 mm and the other who offers sentinel node mapping to women with grade 3 tumors. 60 women (26%) underwent sentinel node mapping along with appropriate surgery directed to the breast. Women were offered risk-adjusted adjuvant radiotherapy and anti-endocrine therapy.
At a median follow-up of 18 months (range 6–132 months), 9 women (15%) were identified with regional axillary nodal disease. A statistical analysis was conducted between women who did or did not undergo sentinel node mapping because there was overlap in large tumor size and high grade between the two groups. A univariate logistic regression statistic showed a trend toward a significant relationship between grade 3 tumors and a risk of occult nodal involvement. This was not confirmed by multivariate analysis.
In our moderate-sized surgical experience evaluating women with pure DCIS who underwent a sentinel node mapping due to large tumor size or high grade histology, we were unable to confirm that either is predictive of occult node involvement.
KeywordsDCIS Sentinel node mapping Tumor grade Tumor diameter
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to disclose.
- 2.Duffy SW, Dibden A, Micalopoulos D, Offman J, Parmar D, Jenkins J, Collins B, Robson T, Scorfield S, Green K, Hall C, Liao XH, Ryan M, Johnson F, Stevens G, Kearins O, Sellars S, Patnick J. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol. 2016;17(1):109–14.CrossRefGoogle Scholar
- 3.Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, Viale G, Veronesi U. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast. The experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg. 2008;247(2):315–9.CrossRefGoogle Scholar
- 4.Maffuz A, Barroso-Bravo S, Najera I, Zarco I, Alvarado-Cabrero I, Rodriguez-Cuevas SA. Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res. 2006;25(2):223–7.Google Scholar
- 5.Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006;107(8):1760–8.CrossRefGoogle Scholar
- 11.Nicholson S, Hanby A, Clements K, Kearins O, Lawrence G, Dodwell D, Bishop H, Thompson A, On behalf of the Sloane Project Steering Group. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence form the UK NHS breast screening programme audit of screen detected DCIS. EJSO. 2015;41:86–93.CrossRefGoogle Scholar
- 13.Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, Liberman L, Turner RR, Lagios MD, Cody HS, Giuliano AE, Silverstein MJ, Van Zee KJ. Outcomes form women with ductal carcinoma in situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol. 2007;14(10):2911–7.CrossRefGoogle Scholar
- 14.Meretoja TJ, Heikkila PS, Salmenkivi K, Leidenius MHK. Outcome of patients with ductal carcinoma in situ and sentinel node biopsy. Ann Surg Oncol. 2012;19:2245–351.Google Scholar